Jacobio Pharmaceuticals outlicensed its phase I pan‑KRAS inhibitor JAB‑23E73 to AstraZeneca in a deal worth up to $1.915 billion; AstraZeneca paid $100 million upfront and will handle development and commercialization outside China, while the companies will co‑develop and commercialize the asset in China. The agreement gives AstraZeneca a broad KRAS program to bolster its oncology pipeline amid rising demand for targeted therapies. Jacobio retains rights in China under a joint development arrangement and stands to receive milestone and royalty payments. The deal underscores Big Pharma’s continued appetite for early‑stage, high‑impact oncology assets from Asia and highlights pan‑KRAS inhibitors as a strategic priority for next‑generation cancer medicines.